Rob Markowitz

Rob Markowitz

Auto-generated profile, based on publicly available information

Rob Markowitz

Evvy, New York, NY 10001, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
KTKrystal Thomas-White
Krystal Thomas-White
GOGenevieve Olmschenk
Genevieve Olmschenk
DLDavid Lyttle
David Lyttle
RMRob Markowitz
Rob Markowitz
PNPita Navarro
Pita Navarro
KMKate McLean
Kate McLean
Bacterial vaginosis (BV) affects 30% of women annually, but many face barriers to in-person care. Here we present real-world outcomes of remote BV diagnosis and management through self-collected vaginal microbiome (VMB) testing and telemedicine visits, focusing on symptom resolution, recurrence, and overall microbial shifts. Among the 1159 study participants, 75.5% experienced symptom resolution at four weeks when managed with our algorithm-guided treatment protocol. At a median follow-up of 4.4 months after the initial visit, 30.0% of patients experienced recurrent BV, which is lower than the typical recurrence rates seen in historical in-person cohorts. Across the entire cohort, metagenomic data demonstrated a significant increase in Lactobacillus abundance (mean of 32.9% to 48.4%, p < 0.0001) and a corresponding decrease in BV-associated taxa such as Gardnerella, Prevotella, and Fannyhessea. A PERMANOVA of pairwise Bray–Curtis distances showed significant separation between pre-and post-treatment samples (pseudo-F = 37.6, p < 0.0001), driven by an increase in Lactobacillus-dominated samples. Treatment adherence was high (a total of 78% reported perfect or near-perfect adherence), and adverse events were generally mild (in total, 22% reported vaginal irritation, and 13% reported abnormal discharge). These results demonstrate that Evvy’s at-home metagenomic platform, paired with telemedicine and a smart treatment algorithm, delivers robust clinical and microbial outcomes. This work offers a novel approach to managing bacterial vaginosis, a challenging condition characterized by persistently high recurrence rates.

8 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
KTKrystal Thomas-White
Krystal Thomas-White
DLDavid Lyttle
David Lyttle
GOGenevieve Olmschenk
Genevieve Olmschenk
RMRob Markowitz
Rob Markowitz
PNPita Navarro
Pita Navarro
KMKate McLean
Kate McLean
Bacterial vaginosis (BV) affects approximately 30% of women annually, with recurrence rates of 50% within 3-6 months despite initial antibiotic treatment. This study evaluates outcomes from a metagenomic-based vaginal microbiome (VMB) test used to personalize BV treatment. A total of 1,159 patients diagnosed with BV received tailored treatment, including antibiotics and adjunctive therapies. Vaginal swabs and symptom data were collected before and after treatment (average 4.4 months). Patients were categorized as responders (symptom improvement) or non-responders (no change or worsening symptoms) based on post-treatment questionnaires. Personalized treatment resulted in a 75.5% response rate, with a recurrence rate of 29.7%. Responders showed a significant reduction in symptom scores (5.2 to 2.4, p< 0.0001). Both groups experienced increased Lactobacillus abundance (responders: 31.1% to 49.9%, p< 0.0001; non-responders: 38.5% to 44.0%, p< 0.05), and decreased BV-associated genera (responders: Gardnerella from 45.1% to 35.2%, p< 0.0001; non-responders: from 43.8% to 37.3%, p< 0.001). Treatment adherence was linked to positive outcomes, with mild adverse events. This study demonstrates that personalized, microbiome-informed therapy improves symptoms and restores vaginal microbiome balance in BV management.